Thyroid Hormones in ADPKD (REORIENTED)
Autosomal Dominant Polycystic Kidney
About this trial
This is an interventional prevention trial for Autosomal Dominant Polycystic Kidney
Eligibility Criteria
Inclusion Criteria: Male and female ≥18 years old; Diagnosis of ADPKD based on renal ultrasonography or genetic test; Written informed consent Exclusion Criteria: Diagnosis of Hashimoto's disease, hyperthyroidism or pituitary disease or any other condition undergoing levothyroxine replacement Patient with hypothyroidism treated with drug therapy Active treatment with Tolvaptan and/or Octreotide-LAR; Regular treatment with amiodarone, lithium, interferon or immunosuppressive drugs including steroids; Active malignancy or acute or chronic inflammatory disease, HIV; Dialysis or kidney transplantation; Diabetes mellitus; Hypocaloric diet or current dietary approaches to obtain weight loss. Legal incapacity or any evidence that the patient will not be able to understand the study aims and procedures.
Sites / Locations
- Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"Recruiting
Arms of the Study
Arm 1
Experimental
ADPKD patients
The study will include 90 patients with diagnosis of ADPKD based on renal ultrasonography findings or genetic test. Specifically, five groups of patients will be identified according to KDIGO classification: 18 subjects with normal or high renal function: eGFR ≥90 ml/min/1.73m2 - CKD G1 stage 18 subjects with mildly decreased renal function: eGFR 89-60 ml/min/1.73m2 - CKD G2 stage 18 subjects with mildly to moderately decreased renal function: eGFR 59 to 45 ml/min/1.73m2 - CKD G3a stage 18 subjects with moderately to severely decreased renal function: eGFR 44 to 30 ml/min/1.73m2 - CKD G3b stage 18 subjects with severely decreased renal function: eGFR 29 to 15 ml/min/1.73m2 - CKD G4 stage.